Seattle Genetics sags as Adcetris sales miss target

Seattle Genetics Inc. (NASDAQ:SGEN) lost $10.05 (15%) to $55.30 on Friday after 3Q18 sales of Adcetris brentuximab vedotin fell short of expectations, and the cancer company predicted relatively flat sales in 4Q18.